Steatohepatitis/Metabolic Liver Disease News

New findings published in Diabetic Medicine highlighted the urgent need for clear, evidence-based guidelines for managing nonalcoholic fatty liver disease in individuals with type 2 diabetes.

In this Healio video exclusive, Steven L. Flamm, MD, chief of the hepatology program at Northwestern Feinberg School of Medicine, discusses the rise in alcohol-related hepatitis during COVID-19, as well as promising new treatment options.

Weight loss induced by FDA-approved endoscopic bariatric and metabolic therapies improved several features of nonalcoholic fatty liver disease, with significant improvement in liver fibrosis, according to research.

As liver transplants significantly increase among older patients, nonalcoholic steatohepatitis has become the most common reason for the procedure in this population, according to a study published in Hepatology Communications.

A new prognostic scoring tool accurately assessed 30-day mortality risk in patients with alcohol-associated hepatitis, according to a study published in Mayo Clinic Proceedings.

High alcohol intake was more frequent following early liver transplant vs. standard transplant in patients with severe alcohol-related hepatitis, according to research published in The Lancet Gastroenterology and Hepatology.

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

The emerging treatment landscape of nonalcoholic steatohepatitis has “exploded” as understanding of the pathogenesis grows, according to a presenter at GUILD 2022.

Vibration-controlled transient elastography and fibrosis-4 index are effective alternatives to liver biopsy when evaluating risk for liver-related events in patients with nonalcoholic fatty liver disease, according to study results.

Increased levels of vitamin D may prevent nonalcoholic fatty liver disease among European populations, according to research published in Clinical Gastroenterology and Hepatology.